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Abstract
Objective
To evaluate if concentrations of the neuronal proteins neurofilament light chain and tau are
changed in women developing preeclampsia and to evaluate the ability of a combination of
neurofilament light chain, tau, S100B and neuron specific enolase in identifying neurologic
impairment before diagnosis of preeclampsia.
Methods
A nested case-control study within a longitudinal study cohort was performed. 469 healthy
pregnant women were enrolled between 2004–2007 and plasma samples were collected at
gestational weeks 10, 25, 28, 33 and 37. Plasma concentrations of tau and neurofilament
light chain were analyzed in 16 women who eventually developed preeclampsia and 36 con-
trols throughout pregnancy with single molecule array (Simoa) method and compared within
and between groups. S100B and NSE had been analyzed previously in the same study pop-
ulation. A statistical model with receiving characteristic operation curve was constructed
with the four biomarkers combined.
Results
Plasma concentrations of neurofilament light chain were significantly increased in women
who developed preeclampsia in gestational week 33 (11.85 ng/L, IQR 7.48–39.93 vs 6.80
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ng/L, IQR 5.65–11.40) and 37 (22.15 ng/L, IQR 10.93–35.30 vs 8.40 ng/L, IQR 6.40–14.30)
and for tau in gestational week 37 (4.33 ng/L, IQR 3.97–12.83 vs 3.77 ng/L, IQR 1.91–5.25)
in contrast to healthy controls. A combined model for preeclampsia with tau, neurofilament
light chain, S100B and neuron specific enolase in gestational week 25 displayed an area
under the curve of 0.77, in week 28 it was 0.75, in week 33 it was 0.89 and in week 37 it was
0.83. Median week for diagnosis of preeclampsia was at 38 weeks of gestation.
Conclusion
Concentrations of both tau and neurofilament light chain are increased in the end of preg-
nancy in women developing preeclampsia in contrast to healthy pregnancies. Cerebral bio-
markers might reflect cerebral involvement before onset of disease.
Introduction
Cerebral complications in preeclampsia are common causes for mortality but are hard to pre-
dict.[1, 2] Some women with preeclampsia and a majority of women with eclampsia exhibit
cerebral oedema known as Posterior Reversible Encephalopathy Syndrome (PRES), secondary
to a compromised blood brain barrier and hyperperfusion.[3] Clinical symptoms and blood
pressure provide poor predictive values for PRES and eclampsia.[4] Early cerebral involvement
in women developing preeclampsia is poorly understood and most research focuses on cere-
brovascular function in women already diagnosed with preeclampsia.[5] These studies are
often limited to retrospective cohort- or animal studies.[6]
Neurofilament light chain (NfL) and tau are neuronal proteins produced in brain tissue,
but mRNA has also been found to a very small extent in extracerebral tissue.[7–10]
Plasma concentrations of S100B and neuron-specific enolase (NSE) are increased in women
developing preeclampsia from gestational week 33 and S100B correlates to presence of neuro-
logical symptoms in women with preeclampsia.[11–13] There are no previous human studies
on the cerebral biomarkers tau and NfL in peripheral blood in pregnancy.
Cerebral biomarkers are promising in combinations to predict adverse outcome in trau-
matic brain injury[14] but has never been investigated in women with preeclampsia.
Ultra-sensitive Single molecule array (Simoa), has emerged for the measurement of very
low concentrations of tau and NfL in plasma and serum.[15, 16] This method has now also
been used to measure the proteins in our cohort of women.
The primary aim in this study was to evaluate if concentrations of NfL and tau are changed
in women developing preeclampsia. The secondary aim was to evaluate the potential cerebral
involvement in women with preeclampsia before onset of disease in a combination model with
peripheral concentrations of NfL, tau, S100B and NSE.
The null hypothesis was that there would be no difference between women developing
preeclampsia and women with normal pregnancies regarding plasma concentrations of NfL
and tau.
Materials and methods
The study was approved by the regional ethics committee at Uppsala University (Ethics com-
mittee reference number 2005:75, date of approval April 6, 2005). Informed consent was
obtained from each woman included in the study.
Cerebral biomarkers in preeclampsia
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Population
The population is described and published earlier.[11, 12] A power calculation was not pos-
sible to perform since the concentrations of the biomarkers in women with preeclampsia
are unknown. A cohort of healthy women (n = 469) was enrolled between gestational week
8–12 at five centres in Va¨rmland, Sweden, during 2004–2007. Preeclampsia was defined as
hypertension (>140/90 mm Hg at two different occasions > 6 hours apart) and proteinuria
(>300 mg/24 hours or >2+ on a dipstick) after 20 weeks of gestation. Exclusion criteria
were chronic hypertension, upper urinary tract infection, pre-existing renal disease or dia-
betes mellitus. Plasma samples were collected at gestational weeks 10, 25, 28, 33 and 37 at
the routine visit to antenatal care. 20 women developed preeclampsia and 16 women had
blood samples available for analysis. A nested case control study was performed where 36
women from the population with healthy pregnancies were randomly selected as controls.
The same cases and controls that were used for earlier publications were also used in this
study, resulting in the number of 36 controls with available samples.
Sample collection
Blood samples were collected in Li/Hep tubes and after centrifugation that occurred within 30
minutes, plasma was frozen in cryotubes at -70˚C until analyzed. Mean storage time until ana-
lyze was four years for S100B, seven years for NSE and nine years for NfL and tau. All samples
were frozen in aliquots after a maximum time of 60 minutes, handled according to the same
routine and thawed only for analysis of S100B, NSE, NfL or tau.
Electrochemiluminescence immunoassay and Simoa
The plasma NfL concentration was measured using an in house Single molecule array (Simoa)
method as previously described in detail.[17] The plasma tau concentration was measured
using the Human Total Tau 2.0 kit and the Simoa platform (Quanterix, Lexington, MA) as
previously described in detail.[18] All measurements were performed in one round of experi-
ments using one batch of reagents by board-certified laboratory technicians who were blinded
to clinical data. Intra-assay coefficients of variation were 11–12% for NfL and 7.4–8.4% for tau.
Enzyme linked immunosorbent assay
Plasma S100B and NSE concentrations were measured by ELISA and published previously in
the same population.[11, 12] The samples were run according to the manufacturer’s recom-
mendation and the intra and inter assay coefficient of variation were 4.6 and 2.8% and 4.3 and
3.1% respectively for S100B and NSE.
Statistics
Demographics and clinical characteristics were compared between groups by student’s t-test
for continuous variables and chi square test for proportions. Variables are presented as means
with standard deviations.
For the analyses of NfL and tau, logarithmic values were used to obtain normal distribution.
For comparisons between groups, student t-test was used. For comparisons over time within
groups, paired t-test was used with Bonferroni correction. Values are presented as medians
with interquartile range (IQR).
Receiver operator characteristics (ROC) curves were constructed to determine predictive
ability for preeclampsia in different gestational weeks.
Cerebral biomarkers in preeclampsia
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All statistical tests were 2-tailed. A p-value <0.05 was considered statistically significant.
Statistical analysis was performed using SPSS version 23.0 (IBM SPSS statistics, Armonk, New
York) for MAC software package.
Results
Background characteristics
Maternal characteristics regarding demographics are presented in Table 1. Women devel-
oping preeclampsia did not differ from women with healthy pregnancies concerning age,
parity, smoking status, body mass index (BMI), blood pressure at enrolment or infant birth
weight. Women who developed preeclampsia had higher blood pressure at delivery, a
shorter gestational length and more often used blood pressure medication. Four women
developed early onset preeclampsia (diagnosis 34 weeks of gestation). One woman was
delivered <34 weeks of gestation due to a placental abruption. All other women developed
preeclampsia without end organ involvement. Median gestational age at diagnosis of pre-
eclampsia was at 270 days (38.4 weeks). The earliest diagnosis was at 212 days (30 weeks) of
gestation.
Blood samples from cases and controls have been analyzed for other biomarkers and thus
some samples in different gestational weeks were no longer available at the time for this study.
This is described in detail in the legends of Tables 2 and 3.
Table 1. Background characteristics of the population.
Controls Preeclampsia p-value
(n = 36) (n = 16)
Maternal age (years) 30 ± 4 29 ± 4 0.36
Nulliparous n (%) 21 (60) 13 (81) 0.11
Smokers n (%) 0 0
BMI in first trimester (kg/m2) 24 ± 4 25 ± 5 0.23
BP in first trimester (mmHg)
Systolic 111 ± 10 115 ± 11 0.25
Diastolic 65 ± 8 68 ± 9 0.26
MAP 80 ± 8 84 ± 8 0.20
Gestational age at diagnosis (days) 270 (246.5–283.5)
BP medication n (%) 0 (0) 6 (38) <0.001
Systolic 111 ± 10 115 ± 11 0.25
At delivery
BP (mm Hg)
Systolic 122 ± 14 150 ± 16 <0.001
Diastolic 72 ± 10 98 ± 7 <0.001
MAP 89 ± 10 116 ± 9 <0.001
Gestational length at delivery (weeks) 40.5 ± 1 39.0 ± 3 <0.01
Infant birth weight (g) 3714 ± 375 3587 ± 851 0.59
BP medication n (%) 0 (0) 6 (38) <0.001
Values are presented as mean ± standard deviation and medians with 25th-75th percentile as appropriate and categorical values as numbers (percentage); Student’s t-test;
n, number; BMI, body mass index in early pregnancy; BP, blood pressure; MAP, mean arterial pressure
https://doi.org/10.1371/journal.pone.0196025.t001
Cerebral biomarkers in preeclampsia
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Plasma levels of NfL during pregnancy
In women developing preeclampsia, there was no difference in plasma concentrations of NfL
in gestational week 25 compared to gestational week 10. There was a significant increase in
plasma NfL concentrations in gestational week 28 (p<0.05), 33 (p<0.05) and 37 (p<0.05)
compared to gestational week 10. (Fig 1)
In normal pregnancy, there was no difference in plasma concentrations of NfL in gesta-
tional week 25, 28 and 33 compared to gestational week 10, but there was a significant increase
in gestational week 37 (p<0.05). (Fig 1)
Between groups, plasma concentrations of NfL were similar in gestational weeks 25 and 28
compared to gestational week 10, but women who developed preeclampsia had higher plasma
concentrations of NfL in gestational weeks 33 (p<0.05) and 37 (p<0.01) compared to women
with normal pregnancies. (Table 2)
There was a tendency to increased concentrations of NfL in early onset preeclampsia
compared to late onset preeclampsia in gestational week 33 (24.5, IQR 13.4–64.9 vs 9.15,
Table 2. Concentrations of NfL in plasma during pregnancy in women developing preeclampsia compared to
women with normal pregnancies.
Gestational week Controls (n = 36) Preeclampsia (n = 16)
10 6.55 (3.93–8.20) 6.80 (4.67–8.53)
25 6.80 (3.70–9.25) 7.30 (5.10–10.65)
28 5.90 (4.15–8.80) 8.15 (6.48–19.90)
33 6.80 (5.65–11.40) 11.85 (7.48–39.93)
37 8.40 (6.40–14.30) 22.15 (10.93–35.30)
p<0.05.
p<0.01.
Values are presented as medians (ng/L) with 25th-75th percentile. Statistical analyses were done by students t–test
with logarithmic values for normal distribution.
In week 10, 30 controls and 12 preeclampsia patients had samples available. In week 25, the numbers were 30
controls and 9 preeclampsia. In week 28, the numbers were 29 controls and 10 preeclampsia. In week 33, the
numbers were 30 controls and 6 preeclampsia. In week 37 the numbers were 26 controls and 8 preeclampsia.
https://doi.org/10.1371/journal.pone.0196025.t002
Table 3. Concentrations of tau in plasma during pregnancy in women developing preeclampsia compared to
women with normal pregnancies.
Gestational week Controls (n = 36) Preeclampsia (n = 16)
10 6.24 (4.70–8.42) 5.70 (3.90–8.12)
25 4.25 (3.15–6.94) 3.82 (2.54–4.16)
28 3.84 (3.11–5.46) 2.73 (2.26–5.06)
33 3.32 (2.38–5.45) 4.45 (2.09–5.24)
37 3.77 (1.91–5.25) 4.33 (3.97–12.83)
p<0.05.
Values are presented as medians (ng/L) with 25th-75th percentile. Statistical analyses were done by students t–test
with logarithmic values for normal distribution.
In week 10, 28 controls and 12 preeclampsia patients had samples available. In week 25, the numbers were 30
controls and 9 preeclampsia. In week 28, the numbers were 30 controls and 9 preeclampsia. In week 33, the numbers
were 29 controls and 7 preeclampsia. In week 37 the numbers were 25 controls and 9 preeclampsia.
https://doi.org/10.1371/journal.pone.0196025.t003
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IQR 6.43–26.28 ng/L, p = 0.15) but the numbers were small and the difference was not sta-
tistically significant.
Plasma levels of tau during pregnancy
In women developing preeclampsia, there was no difference in plasma concentrations of tau
throughout pregnancy. (Fig 2)
In normal pregnancy, there was a significant reduction in plasma concentrations of tau in
gestational week 25 (p<0.05), 28 (p<0.001) and 33 (p<0.001) compared to gestational week
10. There was a borderline significant reduction in plasma concentrations of tau between ges-
tational week 10 and 37 (p = 0.06). (Fig 2)
Between groups, there were no statistical significant differences in plasma concentrations of
tau between groups in gestational weeks 10, 25, 28 or 33. In gestational week 37, women with
preeclampsia experienced higher plasma concentrations of tau than women with normal preg-
nancies (p<0.05). (Table 3)
Combination of cerebral biomarkers for preeclampsia. Combination models with ROC
curves were constructed with NSE, S100B, tau and NfL as indicators for cerebral involvement
in preeclampsia in gestational week 10, 25, 28, 33 and 37.
Area under the curve (AUC) in gestational week 10 was 0.67 (0.47–0.88) and in gestational
week 25 the AUC was 0.77 (0.61–0.93). In gestational week 28, AUC was 0.75 (0.56–0.95) and
Fig 1. Plasma levels of neurofilament light chain (NfL) during pregnancy in normal pregnancies and those developing
preeclampsia. Line diagram showing median concentrations with interquartile range (IQR) of NfL during pregnancy in women
developing preeclampsia (red line) and in women with normal pregnancies (blue line). In women developing preeclampsia,
concentrations of NfL were increased in gestational week 28, 33 and 37 compared to gestational week 10 (p<0.05). In healthy
pregnancies, concentrations of NfL increased in gestational week 37 compared to gestational week 10 (p<0.05). Women developing
preeclampsia had increased concentrations of NfL in gestational weeks 33 and 37 in contrast to women with healthy pregnancies
(p<0.05).
https://doi.org/10.1371/journal.pone.0196025.g001
Cerebral biomarkers in preeclampsia
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in gestational week 33 AUC was 0.89 (0.73–1.00). In gestational week 37 the AUC was 0.83
(0.66–1.00). (Fig 3A–3E)
The combination of the four biomarkers was superior to the biomarkers alone or in combi-
nation of two or three (data not shown).
Discussion
Plasma concentrations of both tau and NfL are increased in the end of pregnancy in women
developing preeclampsia in contrast to healthy pregnancies. In the same cohort we have earlier
shown that plasma concentrations of S100B and NSE are also increased in preeclampsia.[11,
12] Together, this supports that the central nervous system (CNS) is affected in preeclampsia
early even in mild to moderate disease. When all four biomarkers of interest were analyzed
together, AUC reached above 0.7 already from gestational week 25, indicating early CNS
involvement months before onset of clinical disease. These findings emphasize the theory that
preeclampsia begins early in gestation.
The strengths of this study are that it is a prospective cohort design, making the population
less prone to bias, it is also a population well characterized concerning diagnosis of preeclamp-
sia. Serial blood samples available throughout pregnancy make it possible to evaluate the bio-
markers before onset of disease. There are also some limitations to the study. A fairly small
number of women developed preeclampsia and the women diagnosed had preeclampsia with-
out cerebral adverse events. The blood samples from healthy pregnant women were not from
Fig 2. Plasma levels of tau during pregnancy in normal pregnancies and those developing preeclampsia. Line diagram showing
median concentrations with interquartile range (IQR) of tau during pregnancy in women developing preeclampsia (red line) and in
women with normal pregnancies (blue line). In women developing preeclampsia, concentrations of tau remained unchanged
throughout pregnancy. In healthy pregnancies, concentrations of tau decreased in gestational week 25, 28 and 33 (p<0.05) and
showed a borderline significant reduction in gestational week 37 compared to gestational week 10 (p = 0.06). Women developing
preeclampsia had increased levels of tau in gestational week 37 in contrast to women with healthy pregnancies (p<0.05).
https://doi.org/10.1371/journal.pone.0196025.g002
Cerebral biomarkers in preeclampsia
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the entire cohort but only from a random sample of controls, limiting the interpretation of
prediction from the results. The ROC curves constructed are based on few individuals and the
models can be over-fitted and should therefore be interpreted with caution. A larger study
needs to confirm these findings. The analyzes were done 9 years after collection of samples
due to that the new ultrasensitive methos (Simoa) has not previously been available and there
have been difficulties to analyze NfL and tau in peripheral blood.
To the best of our knowledge, there are no published data on long-term stability of tau or
neurofilament light (NfL) in frozen blood samples. However, both proteins show long-term
stability in CSF at both -20 and -80 oC and their concentrations are not affected by blood con-
tamination.[19, 20] Further, we have unpublished data showing stability of tau and NfL con-
centrations in both plasma and serum over 4 freeze-thaw cycles (unpublished observation),
suggesting that both proteins are quite stable in blood. If the concentrations would change
slightly over time in frozen conditions, this would the case for both cases and controls, mini-
mizing the potential error in difference between groups. Normally, proteins are stable in fro-
zen conditions and these samples were just frozen once before analysis.
Fig 3. Receiver Operating Characteristic (ROC) curves using S100B, Neuron Specific Enolase (NSE), Nerofilament Light chain (NfL) and tau combined for
determining preeclampsia at specific gestational weeks. a) 10, Area Under the Curve (AUC) = 0.67 (0.47–0.88), p = 0.103, 11 cases and 26 controls. AUC for NfL 0.33
(0.00–0.67), for tau 0.24 (0.00–0.58), for S100B 0.71 (0.39–1.00) and for NSE 0.24 (0.00–0.54). b) 25, AUC = 0.77 (0.61–0.93), p<0.05, 7 cases, 29 controls. AUC for NfL
0.29 (0.00–0.61), for tau 0.38 (0.00–0.78), for S100B 0.38 /0.02–0.74) and for NSE 0.48 (0.12–0.84). c) 28, AUC = 0.75 (0.56–0.95), p<0.05, 7 cases, 27 controls. AUC for
NfL 0.29 (0.00–0.64), for tau 0.05 (0.00–0.18), for S100B 0.45 (0.06–0.85) and for NSE 0.43 (0.05–0.81). d) 33, AUC = 0.89 (0.73–1.00), p<0.01, 6 cases, 28 controls. AUC
for NfL 0.62 (0.17–1.00), for tau 0.57 (0.19–0.95), for S100B 0.95 (0.82–1.00) and for NSE 0.71 (0.37–1.00). e) 37, AUC = 0.83 (0.66–1.00), p<0.01, 8 cases, 24 controls.
AUC for NfL 0.71 (0.24–1.00), for tau 0.31 (0.00–0.65), for S100B 0.69 (0.31–1.00) and for NSE 0.48 (0.06–0.89).
https://doi.org/10.1371/journal.pone.0196025.g003
Cerebral biomarkers in preeclampsia
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In this cohort, the diagnosis of preeclampsia was made on both hypertension and protein-
uria. In the new definition by ISSHP from 2014,[21] preeclampsia diagnosis can be established
without proteinuria if other signs of organ involvement exist. This study was conducted during
a time period when proteinuria was still required for diagnosis. Also, ISSHP still recommends
proteinuria as a requirement for preeclampsia diagnosis in the research setting to ensure more
specificity around the diagnosis.[21]
Plasma concentrations of NfL and tau have been investigated extensively in Alzhemier’s
disease and other CNS disorders[22–24] but have not yet been investigated in preeclampsia.
For tau, the correlation between cerebrospinal fluid (CSF) and plasma concentrations is weak
[18] wherefore other sources of origin (or other potential confounders) of the plasma tau sig-
nal have to be considered. Lederer et al showed that concentrations of tau and phospho-tau-
181 in CSF did not differ between women with preeclampsia and normal pregnant controls at
time of delivery in third trimester.[25] Our finding demonstrates that peripheral circulating
concentrations of tau differ between groups. If one hypothesizes that CSF levels would not dif-
fer between groups also in our study, then the increased peripheral levels of tau could either be
due to confounding sources outside the CNS or an increased secretion of tau into the extracel-
lular space together with an altered blood brain barrier (BBB) that allows increased secretion
of tau into the systemic circulation in preeclampsia. For NfL, the strong correlation of plasma
with CSF NfL concentrations[15] and the lack of influence of BBB injury, as reflected by the
CSF/serum albumin ratio, on serum NfL[26] suggest that the protein is mainly a marker of
CNS neuronal injury. Considering that tau and NfL are predominantly localized in neurons in
the CNS, the most likely explanation for their efflux into the blood would be that at least a cer-
tain degree of neuronal and/or BBB injury occurs even in preeclampsia without clinical signs
of end organ involvement.
There are some promising models for prediction of preeclampsia already in the first trimester
and also in the second trimester.[27] Some of the models predict early onset preeclampsia, others
predict adverse outcome and time to delivery in women with already diagnosed preeclampsia.[2,
27] There is ongoing research to find a predictive model with or without biomarkers to predict
maternal and neonatal complications in women diagnosed with preeclampsia. Studies exploring
clinical predictors include the PREP, PIERS and PETRA cohorts and have mainly focused on
early onset preeclampsia with populations consisting of 946, 636 and 216 women respectively
with complications mainly of sorts other than neurological. The AUC for adverse outcome was
about 0.80.[2, 28] A recent study investigating s-Flt-1/PlGF ratio in a low risk cohort of women
evaluated the risk of severe preeclampsia at 36 gestational weeks with an AUC of 0.81. In this
cohort, there was also a low rate of neurological complications, where 10/109 women with severe
preeclampsia had visual disturbances and no woman had eclampsia.[29]
Cerebral biomarkers in preeclampsia have been investigated mainly with the hypothesis that
they might be useful to avoid cerebral complications in women already diagnosed with pre-
eclampsia.[11–13] Cerebral biomarkers can not be interpreted as possible predictors of onset of
preeclampsia since such a biomarker has to have a high precision and sensitivity before onset of
clinical disease. Though the fact that cerebral biomarkers in combination reach a fairly good
diagnostic accuracy as early as in gestational week 25 is interesting from a pathophysiological
perspective where the maternal brain in preeclampsia might be affected earlier than we previ-
ously thought. This study is not a diagnostic accuracy study but rather a pilot study where our
findings need to be confirmed and explored in other patient populations.
For preeclampsia, with the evidence present today, it might be hard to predict all pre-
eclampsia with one biomarker specifically for the disease since preeclampsia is an endothelial
disease where different organ system are affected differently in different women and over dif-
ferent time periods during gestation.[27] The cerebral biomarkers might have a role either to
Cerebral biomarkers in preeclampsia
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predict early cerebral changes in pregnancy in women who later develop preeclampsia alone
or in combination with other predictors and/or to predict the severity of the disease and poten-
tial cerebral complications once preeclampsia is diagnosed. This study must be considered as a
pilot study and larger cohorts for prediction of preeclampsia or complications of preeclampsia
are needed to confirm our findings.
A reliable cerebral biomarker in women with preeclampsia would be of use when allocating
neuro protective treatment such as magnesium sulphate [30] to reduce the numbers needed to
treat or when deciding to deliver or not, especially in the case of prematurity.[1]
Pathophysiological processes causing preeclampsia lead to endothelial injury and our results
support a possible blood brain barrier compromise alone or in combination with neuronal and
glial damage early in the course of disease. In this material, the source of the increased levels of
the cerebral biomarkers cannot be confirmed.
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